Zhejiang Starry Pharm Co Ltd
Zhejiang Starry Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical raw materials in China and internationally. It operates through Contrast Agent Series, Quinolone Series, CMO/CDMO, and Others segments. The company offers preparation products comprising iohexol, iopamidol, iodixanol, iomeprol, ioversol, and gadoben… Read more
Zhejiang Starry Pharm Co Ltd (603520) - Total Liabilities
Latest total liabilities as of September 2025: CN¥3.24 Billion CNY
Based on the latest financial reports, Zhejiang Starry Pharm Co Ltd (603520) has total liabilities worth CN¥3.24 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zhejiang Starry Pharm Co Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Zhejiang Starry Pharm Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Zhejiang Starry Pharm Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Starry Pharm Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Xinao Textiles Inc
SHG:603889
|
China | CN¥2.63 Billion |
|
Anhui Xinli Finance Co Ltd
SHG:600318
|
China | CN¥2.37 Billion |
|
Sudarshan Chemical Industries Limited
NSE:SUDARSCHEM
|
India | ₹58.35 Billion |
|
Hubei Radio and Television Information Network Co Ltd
SHE:000665
|
China | CN¥5.92 Billion |
|
Qingmu Digital Technology Co.Ltd.
SHE:301110
|
China | CN¥290.42 Million |
|
Jupiter Fund Management Plc
PINK:JFHHF
|
USA | $366.80 Million |
|
MANDARIN ORIENTAL DL-05
F:1C4
|
Germany | €918.90 Million |
|
General Interface Solution GIS Holding Ltd
TW:6456
|
Taiwan | NT$31.79 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Zhejiang Starry Pharm Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Starry Pharm Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Starry Pharm Co Ltd (2011–2024)
The table below shows the annual total liabilities of Zhejiang Starry Pharm Co Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥3.41 Billion | -9.22% |
| 2023-12-31 | CN¥3.76 Billion | +6.42% |
| 2022-12-31 | CN¥3.53 Billion | +31.71% |
| 2021-12-31 | CN¥2.68 Billion | +5.48% |
| 2020-12-31 | CN¥2.54 Billion | +3.48% |
| 2019-12-31 | CN¥2.46 Billion | +14.57% |
| 2018-12-31 | CN¥2.14 Billion | +87.90% |
| 2017-12-31 | CN¥1.14 Billion | +6.98% |
| 2016-12-31 | CN¥1.07 Billion | +4.50% |
| 2015-12-31 | CN¥1.02 Billion | +42.08% |
| 2014-12-31 | CN¥718.34 Million | +15.34% |
| 2013-12-31 | CN¥622.78 Million | +27.47% |
| 2012-12-31 | CN¥488.57 Million | +15.70% |
| 2011-12-31 | CN¥422.27 Million | -- |